

NeoStem®

Fast Facts

Name:	NeoStem, Inc.	Stock Price:	\$0.72	Average Volume (3 mos):	1.3 million
Industry:	Biotech / Cell Therapy	52 Week Range:	\$0.30 – 0.96	Shares Outstanding:	150.2 million
Ticker (Exchange):	NBS (NYSE MKT)	Market Cap:	\$108.1 million		

All figures as of 8/10/12



Established Leader in Cell Therapy Services

- 150 years of combined management expertise in manufacturing, regulatory and commercialization for therapeutics development
- \$8-10 million in annual historic revenues
- East Coast and West Coast cGMP manufacturing facilities

Outsourcers of Cell Therapy Services

- Baxter International Inc.
- ERYtech Pharma SA
- Hackensack University Medical Center
- ImmunoCellular Therapeutics, Ltd.
- IRX Therapeutics
- Islet Sciences, Inc.
- NC Medical Research
- Prima Biomed Ltd.
- RTI Biologics Inc.



Emerging Leader in Cardiovascular Cell Therapy

- Lead product, AMR-001, an autologous adult stem cell therapy for the prevention of major adverse cardiac events following acute myocardial infarction (AMI)
- Launched Phase 2 clinical trial in 1Q-2012, data readouts expected 2H-2013
- Potential for multiple indications beyond STEMI (i.e., congestive heart failure, other related vascular insufficiencies)

PreSERVE AMI Trial Phase 2 Clinical Plan



Indication	Post-AMI preservation of cardiac function
Number of Subjects, Sites	160 patients, 40+ sites
Primary Endpoint	Increased cardiac perfusion
Secondary Endpoints include	Left ventricular ejection fraction, clinical outcomes



In Partnership with
Becton Dickinson (20% Owner)

Immunotherapy Platform

- Immune mediated diseases are a result of imbalance between T effector cells and T regulatory cells
- T-reg therapy represents a novel approach for restoring immune balance by enhancing T-reg cell number/function



Opportunities in Regenerative Medicine

- Very small embryonic-like stem cells, shown to have several characteristics generally found in embryonic stem cells
- Activities have received awards of > \$2.5 million to support this work



Cellular Differentiation with
an Eye Toward Macular
Degeneration

Recent Business Highlights

- NBS stock increased > 50% since 6/18/12 announcement of Erye divestiture (expected to close 4Q2012)
- Company expects \$12.3 million in cash and removal of \$35 million in debt obligations through divestiture
 - 50% of cash already received or in escrow
- 3 month average daily trading volume 1.3 million shares
- Recently achieved the Golden Cross
- \$17.6 million raised 2012 YTD through warrant exercises and equity sales
- Consolidated Boston, MA facility operations into PCT East and West Coast facilities to further cost savings
- Revenues grew 95% for continuing operations for six months ended 6/30/12 compared to prior year period
- Patient enrollment for PreSERVE Phase 2 clinical trial continues – data readout expected near end of 2013
- \$3 million total active government grants awarded for VSEL Technology development
- Recent additions to management – Martin Schmieg, VP, Corporate Development and Jonathan Sackner-Bernstein, MD, FACC, VP, Clinical Development and Regulatory Affairs

NeoStem, Inc. (NYSE MKT: NBS)
420 Lexington Avenue, Suite 450
New York, NY 10170
212.584.4180
www.neostem.com

Dr. Robin L. Smith
Chairman and Chief Executive
Officer
212.584.4174
rsmith@neostem.com

This material contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date hereof, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the successful execution of the Company's business strategy, including with respect to the development of AMR-001 and other cell therapeutics, the future of the cell therapeutics industry, and the closing of the Company's divestiture of its interest in Suzhou Erye Pharmaceutical Co., Ltd. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors including those described under the heading "Risk Factors" in the Company's filings with the Securities and Exchange Commission (www.sec.gov). The Company's further development is highly dependent on future medical and research developments and market acceptance, which is outside its control.